XML 35 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Fair value measurements and investments (Tables)
 9 Months Ended
Sep. 30, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis

The fair value measurements of the Company's financial assets and liabilities measured on a recurring basis were as follows:

 

 

September 30,
2025

 

 

December 31,
2024

 

(U.S. Dollars, in thousands)

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Neo Medical convertible loan agreement

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Neo Medical preferred equity securities

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lattus contingent consideration

 

$

—

 

 

$

—

 

 

$

(7,270

)

 

$

(7,270

)

 

$

(15,400

)

Deferred compensation plan

 

 

—

 

 

 

(1,598

)

 

 

—

 

 

 

(1,598

)

 

 

(1,703

)

Total

 

$

—

 

 

$

(1,598

)

 

$

(7,270

)

 

$

(8,868

)

 

$

(17,103

)
Schedule of Reconciliation of Investments in Equity Securities

The table below presents a reconciliation of the beginning and ending balances of the Company's investment in Neo Medical preferred equity securities:

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

Fair value of Neo Medical preferred equity securities at January 1

 

$

—

 

 

$

4,951

 

Conversion of loan into preferred equity securities

 

 

—

 

 

 

8,224

 

Unrealized loss recognized in other expense, net

 

 

—

 

 

 

(5,372

)

Fair value of Neo Medical preferred equity securities at September 30

 

$

—

 

 

$

7,803

 

Cumulative unrealized loss on Neo Medical preferred equity securities

 

$

—

 

 

$

(6,092

)

 
Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

Lattus Contingent Consideration estimated fair value at January 1

 

$

15,400

 

 

$

8,500

 

Change in fair value recognized in acquisition-related amortization, impairment, and remeasurement

 

 

(1,800

)

 

 

6,210

 

Installment payment

 

 

(6,330

)

 

 

—

 

Lattus Contingent Consideration estimated fair value at September 30

 

$

7,270

 

 

$

14,710

 
Fair Value, Inputs, Level 3 [Member]  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Schedule of Reconciliation For Convertible Loans Measured At Fair Value Using Significant Unobservable Inputs

(Unaudited, U.S. Dollars, in thousands)

 

2025

 

 

2024

 

Fair value of Neo Medical Convertible Loan at January 1

 

$

—

 

 

$

6,760

 

Gain recognized in other comprehensive income

 

 

—

 

 

 

1,671

 

Interest recognized in interest income, net

 

 

—

 

 

 

162

 

Foreign currency remeasurement recognized in other expense, net

 

 

—

 

 

 

(602

)

Expected credit loss recognized in other income, net

 

 

—

 

 

 

260

 

Conversion into preferred equity securities

 

 

—

 

 

 

(8,224

)

Realized foreign currency loss recognized in other expense, net

 

 

—

 

 

 

(27

)

Fair value of Neo Medical Convertible Loan at September 30

 

$

—

 

 

$

—

 
Schedule of Changes in Valuation of Securities

The following table provides quantitative information related to certain key assumptions utilized within the valuation as of September 30, 2025:

(Unaudited, U.S. Dollars, in thousands)

 

Fair Value as of
 September 30, 2025

 

 

Unobservable inputs

 

Estimate

Lattus Contingent Consideration

 

$

7,270

 

 

Counterparty discount rates

 

10.9% - 11.1%

 

 

 

 

 

Revenue risk-adjusted discount rates

 

6.2% - 6.5%